Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28088731 | 1.00 | HCRTR1 (0.35) | HCRTR1HCRTR2RIPK1ALDH1A1SCD | |
| SCHEMBL13505827 | 0.83 | RIPK1 (0.37) | HCRTR1HCRTR2RIPK1ALDH1A1SCD | |
| SCHEMBL14857164 | 0.83 | RIPK1 (0.34) | HCRTR1HCRTR2RIPK1SCDPRCP | |
| SCHEMBL203526 | 0.82 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL47020 | 0.82 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL2708976 | 0.82 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL3781488 | 0.81 | HCRTR1 (0.39) | HCRTR1HCRTR2SCDSCD5 | |
| SCHEMBL27855003 | 0.81 | HCRTR1 (0.39) | HCRTR1HCRTR2SCDSCD5 | |
| SCHEMBL2454437 | 0.80 | HCRTR1 (0.38) | HCRTR1HCRTR2SCDSCD5PRCP | |
| SCHEMBL29136395 | 0.80 | RIPK1 (0.40) | HCRTR1HCRTR2RIPK1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113365995-A | Immunomodulator, composition and method thereof | 贝达药业股份有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-103354808-B | Antiviral compound | ABBVIE 公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2678334-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2651885-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651924-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2640719-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2627651-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012116257-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012083164-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083170-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012051361-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-19 | — | — | WO | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |